Orion stock
Price history
+71.95% over the period1 year: from €59.90 (November 17, 2025) to €103.00 (November 16, 2026), +71.95%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | €103.00 |
| October 30, 2026 | €99.70 |
| September 30, 2026 | €82.70 |
| August 31, 2026 | €78.90 |
| July 31, 2026 | €80.70 |
| June 30, 2026 | €71.70 |
| May 29, 2026 | €71.20 |
| April 30, 2026 | €68.10 |
| March 31, 2026 | €69.50 |
| February 27, 2026 | €67.80 |
| January 30, 2026 | €69.20 |
| December 30, 2025 | €63.30 |
| November 28, 2025 | €61.80 |
| November 17, 2025 | €59.90 |
At a glance
The company
Develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and self-care products across multiple markets
Latest results
Quarter to June 30, 2026 · EPS €1.00 (estimate €0.96)
TickerLandia's take on Orion
- Pricier than usual relative to earnings: P/E on the latest fiscal year 29 vs a median of 24 over its last 9 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 22 vs 21 (+2%) in a group of 10.
- Strong point: Market momentum (97/100 in its group). Weak point: Dividend (28/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−0.58% from the 52-week high
TickerLandia Fingerprint: Orion
Compared with similar companies: very strong momentum, very high financial strength, and very high growth.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh73
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 16.3 82 P/E (trailing 12 months) 22.0 46 Price/book 10.3 85 Price/sales 6.62 78 Profitabilityhigh73
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 67.4% 14 Net margin 30.3% 86 ROE 54.5% 85 ROA 27.4% 98 Operating margin 38.1% 82 Earnings stabilityaverage46
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.1% 38 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthvery high84
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +12.12% 78 Revenue growth (year over year) +28.10% 90 Earnings growth (year over year) +75.00% 85 Financial strengthvery high86
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.05 82 Current ratio 2.72 94 Interest coverage 77.0 82 Debt/equitycounts in reverse: lower means more financial strength 0.09 85 Dividendlow28
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 20 years 34 Payout ratio 38.5% 23 Dividend yield 1.8% 27 Market momentumvery strong97
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +72.77% 95 Distance from 200-day average +35.41% 98 Riskvery low16
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 11.6% 5 Volatility (60 days) 21.6% 27
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Orion is pricier than in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Orion's P/E today is 28.9, above the median of its last 9 fiscal years (23.9; between 17.8 and 28.7 from 2016 to 2025). Orion's P/E (trailing 12 months): 22.0, in line with the median of a group of 10 similar companies (21.5).
Compared with 10 similar companies
| Metric | Orion | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 22.0 | Middle | |
| Operating margin | 38.1% | High | |
| ROE | 54.5% | High | |
| Debt/equity | 0.09 | Low | |
| Price/book | 10.3 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Orion. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€521.6M
Latest quarter · Q2 2026
Net income
€140.2M
Latest quarter · Q2 2026
Quarterly net margin
26.9%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €14.42B
- P/E
- 22.0
- EPS
- €4.68
- Volume
- 3.64K
- Daily trading
- €1.11M
- Dividend yield
- 1.75%
- Last ex-dividend on October 19, 2026
How Orion is changing
All resultsRevenue grew 12.1% a year on average over the last 3 years
Less cash than profit: free cash flow equal to 41% of net income
Returns
Orion returns with dividends
€1,000 invested in Orion 5 years ago, on November 16, 2021, would be worth €3,234 today with dividends reinvested: +223.39% in total, +26.46% per year. On price alone it would be €2,739 (+173.94%).
| Period | Orion | €1,000 becomes |
|---|---|---|
| 1 month | +18.39% | €1,184 |
| 6 months | +52.14% | €1,521 |
| Year to date | +62.72% | €1,627 |
| 1 year | +76.06% | €1,761 |
| 3 years | +206.27% | €3,063 |
| 5 years | +223.39% | €3,234 |
| 10 years | +279.71% | €3,797 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Orion: technical analysis
Orion is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is at its all-time closing high.
- Trend
- Upward
- RSI (14 sessions)
- 84
- Above 70: a strong rise in a short time
- vs 200-session average
- +35.38%
Active signals
RSI above 70: the stock has risen a lot in a short time.
since October 21, 2026
Support and resistance
Price areas where Orion has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€103.00
- Support€81.15−21.21%2 touches, last on September 3, 2026
- Support€75.03−27.15%3 touches, last on October 5, 2026
- Support€71.43−30.65%7 touches, last on May 26, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 21.6%
- Largest fall in the last year
- −11.63%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Orion: seasonality
Average monthly price change over 22 years
Over the last 22 years, the strongest month for Orion has been January: +3.39% on average, positive in 15 years out of 22. The weakest has been March: −2.01% on average, positive in 10 years out of 22. November, the current month, has been positive in 12 years out of 22 (−0.03% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.39% | +2.25% | 15 of 22 |
| February | +0.71% | +0.36% | 12 of 22 |
| March | −2.01% | −1.34% | 10 of 22 |
| April | +1.48% | +0.83% | 14 of 22 |
| May | +1.70% | +4.53% | 13 of 22 |
| June | +1.62% | +0.65% | 13 of 22 |
| July | +1.70% | +3.10% | 13 of 22 |
| August | +0.20% | −2.55% | 9 of 22 |
| September | +1.14% | +2.29% | 13 of 22 |
| October | +1.28% | +0.39% | 11 of 22 |
| November | −0.03% | +1.57% | 12 of 22 |
| December | +2.09% | +2.11% | 17 of 22 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Orion and its competitors
Nubeqa, Stalevo, Burana and the Easyhaler inhalers are among the products most associated with Orion Oyj, a Finnish pharmaceutical group that makes medicines for people and animals, as well as active pharmaceutical ingredients sold to other drug makers. Its prescription range covers Parkinson's disease, prostate cancer, asthma and COPD, heart failure, breast cancer and menopausal symptoms, while its veterinary products include Domitor and Sileo.
- Headquarters
- Espo, Finland
- Employees
- 4,215
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| OrionORNAV | $15.93B | 38.1% | 22.0 | +52.14% |
| RecordatiREC | $12.11B | 32.6% | 21.0 | +2.62% |
| GrifolsGRF | $8.76B | 18.9% | 16.4 | +28.19% |
| BayerBAYN | $61.37B | 16.5% | — | +51.26% |
| VirbacVIRP | $3.28B | 15.8% | 19.1 | +2.00% |
| GSKGSK | $101.36B | 30.5% | 17.9 | +3.57% |
Same industry or related industries, similar size. Compare Orion with its competitors · Full profile
